Cedars-Sinai Cancer | Strategic Alliance Partners

May 05, 2020

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

April 14, 2020

Karen L. Reckamp, MD, MS, provides insight on how she is navigating challenges posed by the COVID-19 crisis.

March 27, 2020

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

March 10, 2020

Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.

March 04, 2020

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

March 02, 2020

Robert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.

February 28, 2020

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

February 28, 2020

Alain C. Mita, MD, discusses the impact of immunotherapy in the frontline and recurrent settings for patients with small cell lung cancer.

February 21, 2020

Jean Lopategui, MD, discusses the use of liquid biopsies in lung cancer.

February 20, 2020

Ronald Natale, MD, expands on the recent developments with immunotherapy in advanced non–small cell lung cancer.

February 20, 2020

Amin J. Mirhadi, MD, discusses novel radiation approaches that are being used in non–small cell lung cancer.

February 20, 2020

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.

February 19, 2020

Karen Reckamp, MD, MS, highlights the different agents that have been developed to target rarer abnormalities in non–small cell lung cancer.

February 19, 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

February 15, 2020

Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

May 09, 2019

Robert A. Figlin, MD, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology/Oncology, deputy director, Integrated Oncology Service Line, and professor of Biomedical Sciences, Medicine, at Cedars-Sinai Medical Center, discusses the toxicity profiles of combinations of immune checkpoint inhibitors and VEGF TKIs in renal cell carcinoma (RCC), as well as research being done to validate potential biomarkers in the space.

April 22, 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the promise of immunotherapy plus TKI combinations in the treatment of patients with renal cell carcinoma.

April 16, 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses next steps for research in the treatment of patients with metastatic renal cell carcinoma.

April 15, 2019

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

March 08, 2019

Edwin M. Posadas, MD, FACP, discusses recent prostate cancer data and sheds light on where emerging therapies may fit into this landscape.